LAL

Associates of Cape Cod, Inc., Recipient of the Pharma Manufacturing 2021 Innovation Award for its PyroSmart NextGen™ recombinant BET reagent

Retrieved on: 
Tuesday, November 16, 2021
Associate, CEO, ACC, U.S. FDA, Nextgen, Partnership, BET, Environment, LAL, Time, Risk, FDA, Fine chemical, Copper

EAST FALMOUTH, Mass., Nov. 16, 2021 /PRNewswire/ --Associates of Cape Cod, Inc. (ACC) proudly announces that it has been awarded the Pharma Manufacturing 2021 Innovation Award for its recently launched recombinant BET reagent, PyroSmart NextGen.

Key Points: 
  • EAST FALMOUTH, Mass., Nov. 16, 2021 /PRNewswire/ --Associates of Cape Cod, Inc. (ACC) proudly announces that it has been awarded the Pharma Manufacturing 2021 Innovation Award for its recently launched recombinant BET reagent, PyroSmart NextGen.
  • The Pharma Manufacturing 2021 Innovation Awardsrecognizes innovation and those who distinguish themselves as technological leaders in the pharmaceutical and equipment technology space.
  • This year's award winners are covered in detail in Pharma Manufacturing Magazine's November 2021 issue, published by Putman Publishing.
  • ACC was selected for the award because its cutting edge PyroSmart NextGen BET reagent uses innovative recombinant cascade technology.

Associates of Cape Cod, Inc., Recipient of the Pharma Manufacturing 2021 Innovation Award for its PyroSmart NextGen™ recombinant BET reagent

Retrieved on: 
Tuesday, November 16, 2021
Associate, CEO, ACC, U.S. FDA, Nextgen, Partnership, BET, Environment, LAL, Time, Risk, FDA, Fine chemical, Copper

EAST FALMOUTH, Mass., Nov. 16, 2021 /PRNewswire/ --Associates of Cape Cod, Inc. (ACC) proudly announces that it has been awarded the Pharma Manufacturing 2021 Innovation Award for its recently launched recombinant BET reagent, PyroSmart NextGen.

Key Points: 
  • EAST FALMOUTH, Mass., Nov. 16, 2021 /PRNewswire/ --Associates of Cape Cod, Inc. (ACC) proudly announces that it has been awarded the Pharma Manufacturing 2021 Innovation Award for its recently launched recombinant BET reagent, PyroSmart NextGen.
  • The Pharma Manufacturing 2021 Innovation Awardsrecognizes innovation and those who distinguish themselves as technological leaders in the pharmaceutical and equipment technology space.
  • This year's award winners are covered in detail in Pharma Manufacturing Magazine's November 2021 issue, published by Putman Publishing.
  • ACC was selected for the award because its cutting edge PyroSmart NextGen BET reagent uses innovative recombinant cascade technology.

RxSight Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
GLARE, Adoption, Achievement, Carolwood Pacific Railroad, LDD, NASDAQ, Terminology, Technology, Growth, Investment, International, MCI Inc., GLOBE, LAL, IOL, Visual acuity, Patient, Lithium, Telescopic sight, Reinsurance, Risk management

ALISO VIEJO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended September 30, 2021.

Key Points: 
  • ALISO VIEJO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended September 30, 2021.
  • In the third quarter of 2021, total revenue was $5.8 million, an increase of 39% compared to the third quarter of 2020 and 18% growth over the prior quarter ended June 30, 2021.
  • Total operating expenses for the third quarter of 2021 were $14.5 million, a 50% increase from $9.6 million in the third quarter of 2020.
  • On Wednesday, November 10, 2021, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its third quarter 2021 financial results.

Charles River Laboratories Reinforces Commitment to South Carolina

Retrieved on: 
Wednesday, November 10, 2021
Safety, Science, Horseshoe crab, Government, Nature, Intravenous therapy, Horseshoe, Health, COVID-19, Research, Natural Resources, Workforce, Syringe, South Carolina Department of Natural Resources, Partnership, Vaccine, Biotechnology, Company, GLOBE, LAL, Innovation, Â, North Carolina Department of Environmental Quality, Patient, Risk, FDA, Drug development, Pharmaceutical industry

Charleston, S.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Charles River Laboratories International, Inc. is reinforcing its position as an environmental steward and its commitment to the Companys South Carolina operations and the critical role the Charleston-based team plays in the biomedical industry.

Key Points: 
  • Charleston, S.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Charles River Laboratories International, Inc. is reinforcing its position as an environmental steward and its commitment to the Companys South Carolina operations and the critical role the Charleston-based team plays in the biomedical industry.
  • No company has done more to protect and preserve a healthy and growing horseshoe crab population in South Carolinas waterways than Charles River, including supporting the banning of horseshoe crabs for bait in South Carolina, said Foster Jordan, Corporate Senior Vice President, Charles River.
  • Crabs are hand-collected by fishermen licensed by the state of South Carolina and carefully handled in Charles Rivers highly-controlled and monitored lab and then returned to their native waters.
  • In addition to its commitment to the states economy and development, Charles River has been a leader in conservation efforts.

Associates of Cape Cod Inc. Announces the Release of its One Millionth Horseshoe Crab From its Species Sustainability Project

Retrieved on: 
Thursday, November 4, 2021
Safety, Research, ACC, Biotechnology, Technology, Aquaculture, Industry, Quality control, FDA, Horseshoe, Achievement, Dialysis, U.S. FDA, CEO, Tachypleus, BET, Growth, Environment, Biodiversity, Program, Egg, Printing, Culture, Association of Chiropractic Colleges, LAL, Associate

E. FALMOUTH, Mass., Nov. 4, 2021 /PRNewswire/ --ACC proudly announces that it has achieved the release of its millionth juvenile horseshoe crab to the wild, as a result of its species sustainability project.

Key Points: 
  • E. FALMOUTH, Mass., Nov. 4, 2021 /PRNewswire/ --ACC proudly announces that it has achieved the release of its millionth juvenile horseshoe crab to the wild, as a result of its species sustainability project.
  • ACC's reagents are used worldwide in pharmaceutical, medical device, biotechnology, compounding pharmacy and dialysis industries for quality control, product release and research.
  • Unique first of its kind sustainability program rears and releases its millionth juvenile horseshoe crab to the wild.
  • "Our horseshoe crab sustainability project is important to the company and other stakeholders of effected ecosystems", noted Dr. A.J.

Associates of Cape Cod Inc. Announces the Release of its One Millionth Horseshoe Crab From its Species Sustainability Project

Retrieved on: 
Thursday, November 4, 2021
Safety, Research, ACC, Biotechnology, Technology, Aquaculture, Industry, Quality control, FDA, Horseshoe, Achievement, Dialysis, U.S. FDA, CEO, Tachypleus, BET, Growth, Environment, Biodiversity, Program, Egg, Printing, Culture, Association of Chiropractic Colleges, LAL, Associate

E. FALMOUTH, Mass., Nov. 4, 2021 /PRNewswire/ --ACC proudly announces that it has achieved the release of its millionth juvenile horseshoe crab to the wild, as a result of its species sustainability project.

Key Points: 
  • E. FALMOUTH, Mass., Nov. 4, 2021 /PRNewswire/ --ACC proudly announces that it has achieved the release of its millionth juvenile horseshoe crab to the wild, as a result of its species sustainability project.
  • ACC's reagents are used worldwide in pharmaceutical, medical device, biotechnology, compounding pharmacy and dialysis industries for quality control, product release and research.
  • With the goal of maintaining the greatest biodiversity possible, ACC's species sustainability project sources NAHSC eggs and gametes exclusively from crabs destined for terminal use as bait by the fishing industry.
  • "Our horseshoe crab sustainability project is important to the company and other stakeholders of effected ecosystems", noted Dr. A.J.

RxSight to Report Third Quarter 2021 Financial Results on November 10, 2021

Retrieved on: 
Wednesday, October 27, 2021
IOL, Visual acuity, News, International, LAL, Patient, Technology, GLOBE, Investor

ALISO VIEJO, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 10, 2021.

Key Points: 
  • ALISO VIEJO, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 10, 2021.
  • The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.
  • The LAL now features ActivShield technology, a revolutionary UV protection layer built into the lens.

RxSight Announces Updated Date for Reporting Second Quarter 2021 Financial Results on September 9, 2021

Retrieved on: 
Wednesday, September 1, 2021
GLOBE, IOL, Rosh Hashanah, Visual acuity, NASDAQ, LAL, Technology, Patient, Animal, Telescopic sight

ALISO VIEJO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., (NASDAQ: RXST) an ophthalmic medical device company, today announced an updated date for reporting second quarter 2021 financial results.

Key Points: 
  • ALISO VIEJO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., (NASDAQ: RXST) an ophthalmic medical device company, today announced an updated date for reporting second quarter 2021 financial results.
  • In observance of the Rosh Hashanah holiday, the company will now report after the market close on Thursday, September 9, 2021.
  • Management will discuss the results during a conference call beginning that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.

RxSight to Participate in the Wells Fargo Healthcare Conference

Retrieved on: 
Tuesday, August 31, 2021
Interest, GLOBE, IOL, Visual acuity, NASDAQ, Patient, Conference, LAL, Technology, Health insurance

ALISO VIEJO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, today announced plans to participate in the upcoming virtual Wells Fargo Healthcare Conference.

Key Points: 
  • ALISO VIEJO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, today announced plans to participate in the upcoming virtual Wells Fargo Healthcare Conference.
  • RxSights management is scheduled to present Friday, September 10, 2021, at 12:00pm ET.
  • The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
  • The LAL now features ActivShield technology, a revolutionary UV protection layer built into the lens.

RxSight to Report Second Quarter 2021 Financial Results on September 7, 2021 

Retrieved on: 
Tuesday, August 24, 2021
GLOBE, IOL, Visual acuity, LAL, Technology, Patient, Animal, Telescopic sight

ALISO VIEJO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the second quarter of 2021 after the market close on Tuesday, September 7, 2021.

Key Points: 
  • ALISO VIEJO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the second quarter of 2021 after the market close on Tuesday, September 7, 2021.
  • The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.
  • The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.